HTG Overview Video
HTG’s proprietary RNA technologies are designed to help better understand disease and treatment options for patients and to unlock a disruptive approach to drug discovery.
News & Events
HTG Announces Recipients of Its 2020 HTG EdgeSeq Autoimmune Panel Research Grants
TUCSON, Ariz., July 23, 2020 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced Vinodh Pillai, M.D., Ph.D., Assistant Professor of Pathology and Laboratory Medicine at the Children’s Hospital of Philadelphia, and Thomas Dörner, MD, Professor of Rheumatology and Hemostaseology at Charité University Hospitals, Berlin, as award recipients of its 2020 HTG EdgeSeq Autoimmune Panel Research Grants.
- Category:
- News
Investigation of the transcriptional host response to SARS-CoV-2 identifies an imbalance in the host response which drives the development of COVID-19
Problem: SARS-CoV-2 is a novel coronavirus that causes different degrees of morbidity and mortality host response
- Category:
- News
Read the latest news about HTG’s CDx plans and other alliances!
Following End of Qiagen Deal, HTG Molecular to Focus on CDx Plans and Other Alliances
- Category:
- News
HTG EdgeSeq System User Manual RUO Digital Edition
The digital edition of the HTG EdgeSeq System User Manual (RUO) is a new tool designed to stream-line and enhance your customer experience.
- Category:
- News
New publication: Bristol-Myers Squibb study
Reliable Gene Expression Profiling from Clinical Formalin-Fixed, Paraffin-Embedded (FFPE) Specimens Using the HTG EdgeSeq Platform
- Category:
- News
HTG Nominated for a Galien Foundation Medstartup 2018 Award together with Firalis
HTG and Firalis are nominated for Best Innovative Trial Design Leading to Quicker and Better Therapeutic Outcome by the Galien Foundation Medstartup 2018.
- Category:
- News
WIN Consortium to Launch New Precision Oncology Study, Bank Samples for Blood Biomarker Discovery
The Worldwide Innovative Networking (WIN) Consortium at its annual symposium this week provided an update on its precision oncology clinical trial pipeline.
An interview with TJ Johnson on partnering with QIAGEN to provide an entire workflow
Interview with TJ Johnson, CEO of HTG Molecular, on the development of new oncology offerings with pharmaceutical companies and how QIAGEN and HTG have partnered to provide an entire workflow from biomarker discovery to companion diagnostic development.
- Category:
- News
An Interview with Institute of Oncology Research, Dr. Francesco Bertoni, MD
"The HTG EdgeSeq technology represents a nice way to combine the possibility of working with FFPE specimens and next-generation approaches. Moreover, the HTG EdgeSeq Oncology Biomarker Panel (OBP) can be applied on in vitro models and then the results can be validated on FFPE specimens from clinical studies using the same assay." Dr. Bertoni, MD
- Category:
- News
A QIAGEN interview with John Lubniewski on the importance of Immuno-Oncology
A QIAGEN interview with John Lubniewski at the 2017 ASCO Conference on the importance of Immuno-Oncology
- Category:
- News
HTG and Red Nose Day!
HTG is proud to support Red Nose Day and we’re doing our part to end child hunger.
Page last updated March 20, 2023